Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PET FDG studies in oncology

R A Hawkins1, C K Hoh

  • 1Department of Radiology, University of California, San Francisco 94143-0252, USA.

Nuclear Medicine and Biology
|July 1, 1994
PubMed
Summary

Positron emission tomography (PET) using 2-[F-18]fluoro-2-deoxy-D-glucose (FDG) is a valuable tool for cancer detection, staging, and treatment monitoring across various tumors. This method visualizes neoplasms by exploiting their high glycolytic rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours.

British journal of cancer·2014
Same author

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease.

Neurology·2009
Same author

Improved membrane protein solubilization and clean-up for optimum two-dimensional electrophoresis utilizing GLUT-1 as a classic integral membrane protein.

Journal of neuroscience methods·2009
Same author

FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia.

Bone marrow transplantation·2003
Same author

Outcome after extended follow-up in a prospective study of operable breast cancer: key factors and a prognostic index.

British journal of cancer·2002
Same author

The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer.

Clinical nephrology·2002

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Medical Imaging

Background:

  • Positron emission tomography (PET) with 2-[F-18]fluoro-2-deoxy-D-glucose (FDG) is a key imaging modality in oncology.
  • FDG-PET is utilized for cancer detection, staging, and monitoring treatment response.

Purpose of the Study:

  • To review the utility of FDG-PET in various cancer types.
  • To highlight the role of FDG-PET in clinical and research settings.

Main Methods:

  • Utilizes the glucose analog 2-[F-18]fluoro-2-deoxy-D-glucose (FDG) as a radiotracer.
  • Employs standard transaxial imaging and whole-body PET imaging techniques.

Main Results:

  • FDG-PET demonstrates effectiveness in visualizing a wide range of neoplasms.
  • Clinically relevant results are predominantly available for FDG-PET compared to other radiopharmaceuticals.
  • Aggressive neoplasms with high glycolytic rates are particularly well-visualized.

Conclusions:

  • FDG-PET is an established and versatile imaging method for comprehensive cancer management.
  • Its ability to detect and monitor various cancers makes it invaluable in clinical practice and research.

Related Experiment Videos